9 Literaturverzeichnis

Zitierte Literatur in verwendeter Reihenfolge:

1 Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W. Dermatologische Qualitätssicherung (Leitlinien und Empfehlungen). ABW Wissenschaftsverlag 2005;4:205- 234

2 Armstrong BK, Kricker A. Cutaneous melanoma. Cancer Surv 1994;19-20:219-240

3 Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001;14:280-290

4 Lehnert M, Eberle A, Hentschel S, et al. Das maligne Melanom der Haut in epidemiologischen Krebsregistern in Deutschland – Inzidenz, klinische Parameter, Variationen in der Erhebung. Gesundheitswesen 2005;67:729-35

5 Schmidt M, Hölzel D. Klinisch-epidemiologische Daten zum malignen Melanom aus dem Bereich des Tumorzentrums München. 2000, Manual Maligne Melanome, Tumorzentrum München

6 Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic nevis as amajor risk factor for malignant melanoma. J Am Acad Dermatol 1987;17:459-468

7 MacKie RM, Freudenberg T, Aitchison TC. Personal risk-factor chart for cutaneous melanoma. Lancet 1989;2:487-490

8 Garbe C, Büttner P, Weiss J, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol 1994;102:695-699

9 Greene MH, Clark WHJ, Tucker MA, Kraemer KH, Elder DE, Fraser MC. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985;102:458-465

10 Wieker TS, Luther H, Buettner P, Bauer J, Garbe C. Moderate sun exposure and nevus counts in parents are associated with development of melanocytic nevi in childhood. Cancer 2003;97:628-638

11 Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365(9460):687-701

12 Breslow A. Thickness, Cross-sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma. Ann Surg 1970;172 (5):902-08

13 Clark WH, From L, Bernardino EA, Mihm MC. The Histogenesis and Biologic Behavior of Primary Human Malignant Melanomas of the Skin. Cancer Res 1969;29:705-26

14 Balch CM, Soong SJ, Gershenwald JE, et al. "Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system" J Clin Oncol 2001;19:3622-34

15 Eigentler TK, Radny P, Kamin A, et al. Erfahrungen mit der neuen American Joint Committee on Cancer (AJCC)-Klassifikation des kutanen malignen Melanoms. JDDG 2005;3:592-98

16 Breuninger H. Kettelhack C. Therapie des primären und metastasierten Melanoms. Onkologe 2001;7:36-4

17 Roberts DL, Anstey AV, Barlow RJ, et al. Melanoma Study Group. U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 2002;146;7-17

18 Sober AJ, Chuang TY, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001;45:579-586

19 Kaufmann R, Tilgen W, Garbe C. Diagnostische und Therapeutische Standards in der Dermatologischen Onkologie. Hautarzt 1998;49:30-38

20 Kaufmann R. Surgical managament of primary melanoma. Clin Exp Dermatol 2000;25:476-481

21 Bogle M, Kelly P, Shenaq J, Friedman J, Evans GR. The role of soft tissue reconstruction after melanoma resection in the head and neck. Head Neck 2001;23(1):8-15

22 Möhrle M, Breuninger H. Sentinel node biopsy: Welche Aussagen sind gesichert? Hautarzt 2005;Mar 15 German

23 Uren RF. Sentinel Lymph Node Biopsy in Melanoma. J Nucl Med 2006;47(2):191-95

24 Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9

25 Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma Patients. J Clin Oncol 1999;17:976-83

26 Starz H, Cochran AJ, Balda B-R. Die Sentinel-Lymphonodektomie aus histopathologischer Sicht. Akt Dermatol 2002; 28:273-178

27 Essner R, Conforti AM, Kelley M, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early stage melanoma. Ann Surg Oncol 1999;6:442-449

28 Wagner JD, Corbett L, Park HM, et al. Sentinel Lymph Node Biopsy for Melanoma: Experience with 234 Consecutaive Procedures. Plast Reconstr Surg 1999;105:1956-66

29 Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 1999;44:607-618

30 Stevens G, Thompson JF, Firth I, O'Brien CJ, McCarthy WH, Quinn MJ. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 2000;88: 88-94

31 Cooper JS, Chang WS, Oratz R, Shapiro RL, Roses DF. Elective radiation therapy for high-risk malignant melanomas. Cancer 2001;7(6):498-502

32 Schmid-Wendtner MH, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol. 2000;43(3):477-82

33 Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol. 2002;146(6):1042-6

34 Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha-2b as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998;351:1905 –1910

35 Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon-alpha2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998;16:1425-1429

36 Cameron DA, Cornbleet MC, MacKie RM, Hunter JA, Gore M, Hancock B, Smyth JF. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 2001;84:1146-1149

37 Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma. The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17

38 Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high risk melanoma: first analysis of intergroup trial E 1690. J Clin Oncol 2000;18:2444-2458

39 Scolyer RA, Li L-XL, McCarthy SW, et al. Micromorphometric Features of Positive Sentinel Lymph Nodes Predict Involvement of Nonsentinel Nodes in Patinets With Melanoma. Am J Clin Pathol 2004:122:532-539

40 Ziegler A, Lange S, Bender R. Überlebnszeitanalyse: Eigenschaften und Kaplan-Meier Methode. Dtsch Med Wochenschr 2002;127:14-16

41 Ziegler A, Lange S, Bender R. Überlebenzeitanalyse: Cox-Regression. Dtsch Med Wochenschr 2004;129:1-3

42 Ziegler A, Lange S, Bender R. Logistische Regression. Dtsch Med Wochenschr 2002;127: 11-13

43 Weiß C. Basiswissen Medizinische Statistik mit Epidemiologie, Springerverlag 2005

44 van Akkooi ACJ, de Wilt JHW, Verhoef C, et al. High positive sentinel node identifictaion rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer 2006;42:372-80

45 Lee JH, Essner R, Torisu-Itakura H, Wanek L, Wang H, Morton DL. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 2004;22(18):3677-84

46 McMasters KM, Wong SL, Edwards MJ, et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 2001;130:151-6

47 MacNeill KN, Ghazarian D, McCready D, Rotstein L. Sentinel Lymph Node Biopsy for Cutaneous Melanoma of the Head and Neck. Ann Surg Oncol 2005;12(9):726-732

48 Stewart LE, Douglas ST, Vollmer RT. The Importance of Total Number of Sentinel Lymph Nodes in Patients With Stage N0 Cutaneous Melanoma. Am J Clin Pathol 2005;124:77-82

49 Topping A, Dewar D, Rose V, Cavale N, et al. Five years of sentinel node biopsy for melanoma: the St George's Melanoma Unit experience. Br J Plast Surg 2004;57:97-104

50 Statistisches Bundesamt Deutschland. Körpermaße der Bevölkerung nach Altersgruppen Ergebnisse der Mikrozensus-Befragung im Mai 2003, Internetquelle: http://www.destatis.de/basis/d/gesu/gesutab8.php

51 Thune I, Olsen A, Albrektsen G, Tretli S. Cutaneous malignant melnaoma: association with height, weight and body-surface area. A prospective study in Norway. Int J Cancer 1993;55(4):555-61

52 Gallus S, Naldi L, Martin L, Martinelli M, La Vecchia C. Anthropometric measures and risk of cutaneous malignant melanoma: a case-control study from Italy. Melanoma Res 2006;16:83-87

53 Veierod MB, Thielle DS, Laake P. Diet and risk of cutaneous malignant melanoma: prospective study of 50,757 Norwegian men and women. In J Cancer 1997;71:600-04

54 Carli P, Chiarugi A, De Giorgi V. Examination of lesions (including dermoscopy) without contact with the patient is associated with improper management in about 30 % of equivocal melanomas. Dermatol Surg 2005;31(2):169-72

55 Martin RCG, Scoggins CR, Ross MI, et al. Is incisional biopsy of melanoma harmful? Am J Surg 2005;190:913-17

56 Weyers W, Euler M, Diaz-Cascajo C, Schill W-B, Bonczkowitz M. Classification of Cutaneous Malignant Melanoma. Cancer 1999;86:288-99

57 Busam KJ. Lack of relevant information for tumor staging in pathology reports of primary cutaneous melanoma. Am J Clin Pathol 2001;115:743-746

58 Rossi CR, Scagnet B, Vecchiato A, et al. Sentinel node biopsy and ultrasound scanning in cutaneous melanoma: clinical and technical considerations. Eur J Cancer 2000;36:895-900

59 Eigentler TK, Buettner PG, Leiter U, Garbe C. Impact of Ulceration in Stages I to III Cutaneous Melanoma As Staged by the American Joint Committee on Cancer Staging System: An Analysis of the German Central Malignant Melanoma Registry. J Clin Oncol 2004;22:4376-83

60 Homsi J, Kashani-Sabet M, Messina JL, Daud A. Cutaneous Melanoma: Prognostic Factors. Cancer Control 2005;12(4):223-29

61 Purdue MP, From L, Armstrong BK, et al. Etiologic and Other Factors Predicting Nevus-Associated Cutaneous Malignant Melanoma. Cancer Epidemiol Biomearkers Prev 2005;14(8):2015-22

62 Carli P, Massi D, Santucci M, Biggeri A, Giannotti B. Cutaneous melanoma histologically associated with a nevus and melanoma de novo have a different profile of risk: results from a case-control study. Am Acad Dermatol 1999;40(4):549-57

63 Roka F, Kittler H, Cauzig P, et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer 2005;92(4):662-7.

64 Chakera AH, Drzewiecki KT, Eigtved A, Juhl BR. Sentinel node biopsy for melanoma: a study of 241 patients. Melanoma Res. 2004;14(6):521-6

65 Gutzmer R, Al Ghazal M, Geerlings H, Kapp A. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol 2005;153:1137-41

66 Cammarota T, Pinto F, Magliaro A, Sarno A. Current uses of diagnostic high-frequency US in dermatology. Eur J Radiol 1998;27(2):215-23

67 Schmid-Wendtner MH, Burgdorf W. Ultrasound scanning in dermatology. Arch Dermatol 2005;141(2):217-24

68 Reali UM, Santucci M, Paoli G, Chiarugi C. The use of high resolution ultrasound in preoperative evaluation of cutaneous malignant melanoma thickness. Tumori 1989;75(5):452-5

69 Solivetti FM, Thorel MF, DiLuca Sidozzi A, Bucher S, Donati P, Panichelli V. Role of high-definition and high frequency ultrasonography in determining tumor thickness in cutaneous malignant melanoma. Radiol Med (Torino) 1998;96(6):558-61

70 McMasters KM, Noyes RD, Reintgen DS, et al. Lessons Learnd From the Sunbelt Melanoma Trial. J Surg Oncol 2004;86:212-23

71 Morton DL, Cochran AJ, Thompson JF, et al. Sentinel Node Biopsy for Early-Stage Melanoma: Accuracy and Morbidity in MSLT-I, an International Multicenter Trial. Ann Surg 2005;242(3):302-313

72 Albertinii JJ, Cruse CW, Rapaport D, et al. Intraoperative radiolymph-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996;223:217-24

73 Krag DN, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995;130:654-8

74 Maccauro M, Villano C, Aliberti G, et al. Lymphoscintigraphy with intraoperative gamma probe sentinel node detection: clinical impact in patients with head and neck melanomas. Q J Nucl Med Mol Imaging 2005;49(3):245-51

75 McMasters KM, Reintgen DS, Ross MI, Wong SL, Gershenwald JE. Sentinel lymph node biopsy for melanoma: How many radioactive nodes should be removed? Ann Surg Oncol 2001:8:192-97

76 Carlson GW, Murray DR, Lyles RH, Hestley A, Cohen C. Sentinel lymph node biopsy in the management of cutaneous head and neck melanoma. Plast Reconstr Surg 2005;115(3):721-8.

77 O'Brien CJ, Uren RF, Thompson JF, et al. Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. Am J Surg 1995;170:461-6

78 Leong SP, Morita ET, Sudmeyer M, et al. Heterogeneous patterns of lymphatic drainage to sentinel lymph nodes by primary melanoma from different anatomic sites. Clin Nucl Med 2005;30(3):150-8

79 de Wilt JHW, Thompson JF, Uren RF, et al. Correlation Between Preoperative Lymphoscintigraphy and Metastatic Nodal Disease Sites in 362 Patients With Cutaneous Melanomas of the Head and Neck. Ann Surg 2004;239:544-52

80 Arens A, Osgina J, Schwipper V et al. Sentinel-Lymphknoten-Dissektion beim malignen Melanom. Chirurg 2003;74:665-670

81 Coit DG. The “true” sentinel lymph node: in search of an operational definition of a biological phenomenon. Ann Surg Oncol 2001;8(3):187-89

82 Rossi CR, De Slavo GL, Trifiró G, et al. The impact of lymphoszintigraphy technique on the outcome of snetinel node biopsy in 1,313 patinets with cutahneous melanoma: an Italian multicentric study. J Nucl Med. 2006;47:234-241

83 Roaten JB, Pearlman N, Gonzalez R, McCarter MD. Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg 2005;140(1):85-9

84 Cochran A. The pathologists role in sentinel lymph node evaluation [Review]. Semin Nucl Med 2000;30(1):11-17

85 Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48

86 Spatz A, Cook MG, Elder DE et al. Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. Eur J Cancer 2003;39:1861-65

87 Scolyer RA, Li LX, McCarthy SW, et al. Immunohistochemical stains fail to increase the detection rate of micrometastatic melanoma in completion regional lymph node dissection specimens. Melanoma Res 2004;14(4):263-8

88 Cochran AJ, Roberts A, Wen DR, et al. Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumours. Pathology 2004;36(5):478-84

89 Fink AM, Weihsengruber F, Spangl B, et al. S-classification of sentinel lymph node biopsy predicts the results of complete regional lymph node dissection. Melanoma Res 2005;15(4):267-71

90 Kaleya RN, Heckman JT, Most M, Zager JS. Lymphatic mapping and sentinel node biopsy: a surgical perspective. Semin Nucl Med 2005;35(2):129-34

91 Hocevar M, Bracko M, Pogacnik A, et al. The role of preoperative ultrasonography in reducing the number of sentinel lymph node procedures in melanoma. Melanoma Res 2004;14:533-36

92 Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002;147:62-70

93 Pawlik TM, Ross MI, Thompson JF, Eggermont AMM, Gershenwald JE. The Risko of In-Transit Melanoma Metastasis Depends on Tumor Biology and Not the Surgical Approach to Regional Lymph Nodes. J Clin Oncol 2005;23(21):4588-4590

94 Fincher TR, McCarthy TM, Fisher TL. Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma. Am J Surg 2003;186:675-81

95 Yee VS, Thompson JF, McKinnon JG, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol 2005;12(6):429-39

96 Wagner JD, Ranieri J, Evdokimow DZ, et al. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg. 2003;112(2):486-97

97 Vucetic B, Andreja Rogan S, Balenovic A, et al. The role of preoperative lymphoscintigraphy in surgery planning for sentinel lymph node biopsy in malignant melanoma. Wien Klin Wochenschr. 2006;118(9-10):286-93

98 Cecchi R, De Gaudio C, Buralli L, Innocenti S. Lymphatic mapping and sentinel lymph node biopsy in the management of primary cutaneous melanoma: report of a single-centre experience. Tumori. 2006;92(2):113-7

99 Starz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 2004;11(3):162-8

100 Buettner PG, Leiter U, Eigentler TK, Garbe C. Development of Prognostic Factors and Survival in Cutaneous Melanoma over 25 Years. Cancer 2005;103:616-24

101 Shivers S, Alsarraj M, Guiliano R, Jakub J, Pendas S, Reintgen D. Molecular staging of melanoma. Ann Surg Oncol 2004;11(11):953-4

102 Möhrle M, Schippert W, Rassner G, Garbe C, Breuninger H. Is Sentinel Lymph Node Biopsy of Therapeutic Relevance for Melanoma? Dermatology 2004;209:5-13

103 Lloyd MS, Topping A, Allan R, Powell B. Contraindications to sentinel lymph node biopsy in cutaneous malignant melanoma. Br J Plast Surg 2004;57(8):725-7

104 Medalie N, Ackerman AB. Sentinel node biopsy has no benefit for patients whose primary cutaneous melanoma has metastasized to a lymph node and therefore should be abandoned now. Br J Dermatol 2004;151(2):298-307

105 Kretschmer L, Bertsch HP, Meller J. Sentinel-Lymphonodektomie beim malignen Melanom – ein Update. JDDG 2003;1:777-84

106 Balch CM, Soong SJ, Bartolucci AA et al. Efficacy of an elective regional lymph node dissection of 1-4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-63

107 Balch CM, Soong S, Ross MI et al. Long-term results of a multi-institutional randomized trialcomparing prognostic factors and surgical results for intermediate thickness melanomas (1.0-4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000;7:87-97

108 Hafner J, Schmid MH, Kempf W, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol 2004;150:677-86

109 Garbe C, Schadendorf D. Surveillance and Follow-up Examinations in Cutaneous Melanoma. Onkologie 2003;26:241-46

110 Salti GI, Kansagra A, Warso MA, Ronan SG, Da Gupta TK. Clinical Node-Negative Thick Melanoma. Arch Surg 2002;137:291-295

111 Jahn V, Breuninger H, Garbe C, Moehrle M. Melanoma of the ear: prognostic factors and surgical strategies. Br J Dermatol 2006;154:310-18

112 Leiter U, Buettner PG, Eigentler TK, Garbe C. Prognostic Factors of Thin Cutaneous Melanoma: An Analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. J Clin Oncol 2004;22:3660-7

113 Stitzenberg KB, Groben PA, Stern SL, Thomas NE, Hensing TA, Sansbury LB, Ollila DW. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or = 1.0 mm). Ann Surg Oncol 2004;11(10):900-6